Rakovina Therapeutics Stock Probability of Future Stock Price Finishing Under 0.06
| RKV Stock | CAD 0.06 0.01 9.09% |
Rakovina |
Rakovina Therapeutics Target Price Odds to finish below 0.06
The tendency of Rakovina Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 0.06 | 90 days | 0.06 | about 1.19 |
Based on a normal probability distribution, the odds of Rakovina Therapeutics to move below current price in 90 days from now is about 1.19 (This Rakovina Therapeutics probability density function shows the probability of Rakovina Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the stock has the beta coefficient of 1.01 indicating Rakovina Therapeutics market returns are correlated to returns on the market. As the market goes up or down, Rakovina Therapeutics is expected to follow. Additionally Rakovina Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Rakovina Therapeutics Price Density |
| Price |
Predictive Modules for Rakovina Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rakovina Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Rakovina Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rakovina Therapeutics is not an exception. The market had few large corrections towards the Rakovina Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rakovina Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rakovina Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.6 | |
β | Beta against Dow Jones | 1.01 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.08 |
Rakovina Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rakovina Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rakovina Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rakovina Therapeutics generated a negative expected return over the last 90 days | |
| Rakovina Therapeutics has high historical volatility and very poor performance | |
| Rakovina Therapeutics has some characteristics of a very speculative penny stock | |
| Rakovina Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rakovina Therapeutics has accumulated about 4.37 M in cash with (1.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Rakovina Therapeutics Showcases AI in Cancer Therapy - TipRanks |
Rakovina Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rakovina Stock often depends not only on the future outlook of the current and potential Rakovina Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rakovina Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 70.1 M |
Rakovina Therapeutics Technical Analysis
Rakovina Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Rakovina Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Rakovina Therapeutics. In general, you should focus on analyzing Rakovina Stock price patterns and their correlations with different microeconomic environments and drivers.
Rakovina Therapeutics Predictive Forecast Models
Rakovina Therapeutics' time-series forecasting models is one of many Rakovina Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Rakovina Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Rakovina Therapeutics
Checking the ongoing alerts about Rakovina Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Rakovina Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Rakovina Therapeutics generated a negative expected return over the last 90 days | |
| Rakovina Therapeutics has high historical volatility and very poor performance | |
| Rakovina Therapeutics has some characteristics of a very speculative penny stock | |
| Rakovina Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rakovina Therapeutics has accumulated about 4.37 M in cash with (1.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.06. | |
| Roughly 32.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Rakovina Therapeutics Showcases AI in Cancer Therapy - TipRanks |
Additional Tools for Rakovina Stock Analysis
When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.